Background: Though various neurohormonal systems are concurrently activated during birth, their biological effectors are not always easy to measure due to their short half-life in vivo, instability in biological samples, or very low concentrations. Methods: Using a recently discovered chemiluminescence assay, we measured the stable precursor fragments mid-regional pro-atrial natriuretic peptide (MR-proANP), mid-regional pro-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1) and C-terminal pro-vasopressin (CT-proAVP or copeptin) immediately after birth in umbilical venous cord blood from 119 infants with a gestational age of 23–42 weeks and evaluated their possible functions. Results: Cord blood levels of MR-proANP, MR- proADM, CT-proET-1, and CT-proAVP were considerably higher compared with normal adult levels. The CT-proAVP concentrations were 10-fold higher in term, and 70-fold higher in extremely preterm infants. MR-proANP showed 4-fold higher levels in term infants and 20-fold higher levels in extremely preterm infants. Levels of MR-proADM and CT-proET-1 were 2- to 3-fold higher in preterm and term infants. All four parameters showed significantly decreased values with increasing gestational age and a significant correlation between CT-proET-1 and MR-proADM. Conclusion: Our results indicate that vasoactive and natriuretic mediators play a functionally relevant role in circulatory transition from fetal to neonatal life.

Keywords:
Mid-regional pro-adrenomedullin, C-terminal pro-endothelin-1, C-terminal pro-vasopressin, Vasoactive peptides, Mid-regional pro-atrial natriuretic peptide
1.
Ballevre L, Solhaug MJ, Guignard JP: Nitric oxide and the immature kidney. Biol Neonate 1996;70:1–14.
2.
Heymann MA: Control of the pulmonary circulation in the fetus and during the transitional period to air breathing. Eur J Obstet Gynecol Reprod Biol 1999;84:127–132.
3.
Morgenthaler NG, Struck J, Thomas B, Bergmann A: Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004;50:234–236.
4.
Morgenthaler NG, Struck J, Alonso C, Bergmann A: Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005;51:1823–1829.
5.
Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A: Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem 2006;52:1144–1151.
6.
Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112–119.
7.
Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, Ciricugno S, Milani V, Marchioli R, Struck J, Bergmann A, Maggioni AP, Tognoni G, Tavazzi L: The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 2010;12:338–347.
8.
Kääpä P, Seppänen M, Kero P, Ekblad H, Arjamaa O, Vuolteenaho O: Hemodynamic control of atrial natriuretic peptide plasma levels in neonatal respiratory distress syndrome. Am J Perinatol 1995;12:235–239.
9.
Shaffer SG, Geer PG, Goetz KL: Elevated atrial natriuretic factor in neonates with respiratory distress syndrome. J Pediatr 1986;109:1028–1033.
10.
Semmekrot B, Guignard JP: Atrial natriuretic peptide during early human development. Biol Neonate 1991;60:341–349.
11.
Ignarro LJ, Wood KS, Harbison RG, Kadowitz PJ: Atriopeptin II relaxes and elevates cGMP in bovine pulmonary artery but not vein. J Appl Physiol 1986;60:1128–1133.
12.
Hargrave B, Roman C, Morville P, Heymann M: Pulmonary vascular effects of exogenous atrial natriuretic peptide in sheep fetuses. Pediatr Res 1990;27:140–143.
13.
Adnot S, Chabrier PE, Andrivet P, Viossat I, Piquet J, Brun-Buisson C, Gutkowska Y, Braquet P: Atrial natriuretic peptide concentrations and pulmonary hemodynamics in patients with pulmonary artery hypertension. Am Rev Respir Dis 1987;136:951–956.
14.
Hadeed AJ, Leake RD, Weitzman RE, Fisher DA: Possible mechanisms of high blood levels of vasopressin during the neonatal period. J Pediatr 1979;94:805–808.
15.
Wellmann S, Benzing J, Cippa G, Admaty D, Creutzfeldt R, Mieth RA, Beinder E, Lapaire O, Morgenthaler NG, Haagen U, Szinnai G, Buhrer C, Bucher HU: High copeptin concentrations in umbilical cord blood after vaginal delivery and birth acidosis. J Clin Endocrinol Metab 2010;95:5091–5096.
16.
Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M: Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007;28:219–226.
17.
Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, Muller K, Meckel S, Gass A, Kappos L, Steck AJ, Engelter ST, Muller B, Christ-Crain M: Copeptin: A novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009;66:799–808.
18.
Kleindienst A, Brabant G, Morgenthaler NG, Dixit KC, Parsch H, Buchfelder M: Following brain trauma, copeptin, a stable peptide derived from the AVP precusor, does not reflect osmoregulation but correlates with injury severity. Acta Neurochir Suppl 2010;106:221–224.
19.
Isozaki-Fukuda Y, Kojima T, Hirata Y, Ono A, Sawaragi S, Sawaragi I, Kobayashi Y: Plasma immunoreactive endothelin-1 concentration in human fetal blood: its relation to asphyxia. Pediatr Res 1991;30:244–247.
20.
Endo A, Shimada M, Ayusawa M, Minato M, Takada M, Takahashi S, Harada K, Masaoka N, Sato K: Nitric oxide and endothelin 1 during postnatal life. Biol Neonate 1996;70:15–20.
21.
Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K, Matsuo H, Omae T, Matsuoka H: Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994;94:2158–2161.
22.
Shimekake Y, Nagata K, Ohta S, Kambayashi Y, Teraoka H, Kitamura K, Eto T, Kangawa K, Matsuo H: Adrenomedullin stimulates two signal transduction pathways, cAMP accumulation and Ca2+ mobilization, in bovine aortic endothelial cells. J Biol Chem 1995;270:4412–4417.
23.
Ishizaka Y, Tanaka M, Kitamura K, Kangawa K, Minamino N, Matsuo H, Eto T: Adrenomedullin stimulates cyclic AMP formation in rat vascular smooth muscle cells. Biochem Biophys Res Commun 1994;200:642–646.
24.
Maurice DH, Haslam RJ: Nitroprusside enhances isoprenaline-induced increases in camp in rat aortic smooth muscle. Eur J Pharmacol 1990;191:471–475.
25.
Magnusson A, Halldorsson H, Thorgeirsson G, Kjeld M: Endothelin secretion is regulated by cyclic AMP and phosphatase 2A in endothelial cells. J Cell Physiol 1994;161:429–434.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.